TEVA(US:TEVA) Yahoo Finance·2026-01-31 14:35Core Viewpoint - Teva Pharmaceutical Industries Limited is considered one of the best healthcare stocks to buy for 2026, with analysts optimistic about its growth potential despite some revenue headwinds [1][2]. Financial Performance - Teva reported strong Q4 2025 results, with earnings per share (EPS) of $0.96, surpassing the forecast of $0.65, and revenue of $4.71 billion, exceeding expectations of $4.33 billion, aided by a $500 million milestone payment from Sanofi [3]. - However, the company projected lower revenue for 2026, estimating between $16.4 billion and $16.8 billion, along with adjusted EPS of $2.57 to $2.77, reflecting a significant impact from lost sales of its generic Revlimid due to increased competition [3]. Growth Drivers - Teva's innovative portfolio is a key growth driver, with Austedo generating $725 million in U.S. sales in Q4, marking a 40% year-over-year increase. The combined revenue from Austedo, Ajovy, and Uzedy reached $3.1 billion in 2025 and is expected to grow to up to $3.6 billion in 2026 [4]. - Analysts highlight pipeline catalysts, including a potential FDA decision on Olanzapine LAI, which could unlock a $3 billion sales opportunity, supporting Teva's growth narrative [1][2]. Market Position - Teva is recognized as a global leader in generic and specialty medicines, focusing on the development, manufacturing, and marketing of drugs across various therapeutic areas, including central nervous system, respiratory, and oncology [5].